bioAffinity Technologies (BIAF) Stock Price, News & Analysis

Company Overview

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Key Stats

• Today's Range: $0.34 to $0.37
• 50-Day Range: $0.33 to $0.97
• 52-Week Range: $0.26 to $3.16
• Volume: 70,954 shs
• Average Volume: 148,679 shs
• Market Capitalization: $5.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

bioAffinity Technologies Stock Analysis - MarketRank™

bioAffinity Technologies scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

bioAffinity Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

bioAffinity Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of bioAffinity Technologies is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of bioAffinity Technologies is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

bioAffinity Technologies has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.23% of the float of bioAffinity Technologies has been sold short.

Short Interest Ratio / Days to Cover

bioAffinity Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in bioAffinity Technologies has recently decreased by 54.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bioAffinity Technologies does not currently pay a dividend.

Dividend Growth

bioAffinity Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.23% of the float of bioAffinity Technologies has been sold short.

Short Interest Ratio / Days to Cover

bioAffinity Technologies has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in bioAffinity Technologies has recently decreased by 54.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.76

News Sentiment

bioAffinity Technologies has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for bioAffinity Technologies this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.12% of the stock of bioAffinity Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.64% of the stock of bioAffinity Technologies is held by institutions.

BIAF Stock Analysis - Frequently Asked Questions

How have BIAF shares performed this year?

bioAffinity Technologies' stock was trading at $0.91 at the beginning of 2025. Since then, BIAF shares have decreased by 59.7% and is now trading at $0.3670.
View the best growth stocks for 2025 here.

When did bioAffinity Technologies IPO?

bioAffinity Technologies (BIAF) raised $8 million in an IPO on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital served as the underwriter for the IPO and Craft Capital Management was co-manager.

Who are bioAffinity Technologies' major shareholders?

Top institutional shareholders of bioAffinity Technologies include Sheaff Brock Investment Advisors LLC (0.30%).

How do I buy shares of bioAffinity Technologies?

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of bioAffinity Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), AIM ImmunoTech (AIM), Alnylam Pharmaceuticals (ALNY) and Ambrx Biopharma (AMAM).

Company Calendar

• Today: 3/14/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:BIAF
• CIK: 1712762
• Web: www.bioaffinitytech.com
• Phone: 210-698-5334
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +1,552.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,940,000.00
• Net Margins: -91.22%
• Pretax Margin: -90.01%
• Return on Equity: -205.09%
• Return on Assets: -115.95%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 1.02
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $9.37 million
• Price / Sales: 0.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 15,585,000
• Free Float: 10,112,000
• Market Cap: $5.66 million
• Optionable: Not Optionable
• Beta: 3.13